Qian CN, Zhang W, Xu RH. Defeating cancer: the 150 most important questions in cancer research and clinical oncology. Chin J Cancer. 2016;35:104.
Article
PubMed
PubMed Central
Google Scholar
Wee JT, Poh SS. The most important questions in cancer research and clinical oncology. Question 1. Could the vertical transmission of human papilloma virus (HPV) infection account for the cause, characteristics, and epidemiology of HPV-positive oropharyngeal carcinoma, non-smoking East Asian female lung adenocarcinoma, and/or East Asian triple-negative breast carcinoma? Chin. J Cancer. 2017;36:13.
Google Scholar
Venniyoor A. The most important questions in cancer research and clinical oncology—Question 2–5. Obesity-related cancers: more questions than answers. Chin J Cancer. 2017;36:18.
Article
PubMed
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 6–14. Chin J Cancer. 2017;36:33.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 15–24. Chin J Cancer. 2017;36:39.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 25–30. Chin J Cancer. 2017;36:42.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 31–39. Chin J Cancer. 2017;36:48.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 40–49. Chin J Cancer. 2017;36:55.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 50–56. Chin J Cancer. 2017;36:69.
Article
PubMed Central
Google Scholar
Johnston LA. Competitive interactions between cells: death, growth, and geography. Science. 2009;324(5935):1679–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wolford CC, McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, et al. Transcription factor ATF3 links host adaptive response to breast cancer metastasis. J Clin Investig. 2013;123(7):2893–906.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cui J, Mao X, Olman V, Hastings PJ, Xu Y. Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive cancer to grow increasingly faster. J Mol Cell Biol. 2012;4(3):174–6.
Article
PubMed
PubMed Central
Google Scholar
Zhang C, Cao S, Xu Y. Population dynamics inside cancer biomass driven by repeated hypoxia-reoxygenation cycles. Quant Biol. 2014;2(3):85–99.
Article
Google Scholar
Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671.
Article
CAS
PubMed
Google Scholar
Damaghi M, Wojtkowiak JW, Gillies RJ. pH sensing and regulation in cancer. Front Physiol. 2013;4:370.
Article
PubMed
PubMed Central
Google Scholar
Johansson M, Ieong KW, Trobro S, Strazewski P, Åqvist J, Pavlov MY, et al. pH-sensitivity of the ribosomal peptidyl transfer reaction dependent on the identity of the A-site aminoacyl-tRNA. Proc Natl Acad Sci USA. 2011;108(1):79–84.
Article
CAS
PubMed
Google Scholar
Padan E, Venturi M, Gerchman Y, Dover N. Na+/H+ antiporters. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 2001;1505(1):144–57.
Article
CAS
Google Scholar
Slepkov ER, Rainey JK, Sykes BD, Fliegel L. Structural and functional analysis of the Na+/H+ exchanger. Biochem J. 2007;401(Pt 3):623–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Halestrap AP. The monocarboxylate transporter family—structure and functional characterization. IUBMB Life. 2012;64(1):1–9.
Article
CAS
PubMed
Google Scholar
Alwan A. World Health Organization. Disaster Med Public Health Prep. 2007; 1: 7–8.
Hanyin C, Lina Z, David EC. Circulating Plasma MiR-141 Is a Novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE. 2011;6(3):e17745.
Article
Google Scholar
Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569–79.
CAS
PubMed
Google Scholar
Valadi H, Ekström K, Bossios A. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.
Article
CAS
PubMed
Google Scholar
Kosaka N, Iguchi H, Yoshioka Y. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285:17442–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472–8.
Article
PubMed
PubMed Central
Google Scholar
Cho J, Choi SM, Lee J, Lee CH, Lee SM, Kim DW, et al. Proportion and clinical features of never-smokers with non-small cell lung cancer. Chin J Cancer. 2017;36:20.
Article
PubMed
PubMed Central
Google Scholar
Varghese AM, Sima CS, Chaft JE, Johnson ML, Riely GJ, Ladanyi M, et al. Lungs don’t forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol. 2013;8:123–5.
Article
PubMed
PubMed Central
Google Scholar
Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012;118:729–39.
Article
CAS
PubMed
Google Scholar
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, et al. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol. 2017;10:100.
Article
PubMed
PubMed Central
Google Scholar
Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 2006;354:2619–21.
Article
CAS
PubMed
Google Scholar
Kytola V, Topaloglu U, Mille LD, Bitting RL, Goodman MM, D`Agostino RB Jr, et al. Mutational landscapes of smoking-related cancers in caucasians and African Americans: precision oncology perspectives at wake forest baptist comprehensive cancer center. Theranostics. 2017;7:2914.
Article
PubMed
PubMed Central
Google Scholar
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Qian CN, Tan MH, Yang JP, Cao Y. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation. Chin J Cancer. 2016;35:10.
Article
PubMed
PubMed Central
Google Scholar
Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22(43):6810–8.
Article
CAS
PubMed
Google Scholar
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6.
Article
CAS
PubMed
Google Scholar
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
Article
CAS
PubMed
Google Scholar
Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.
Article
PubMed
PubMed Central
Google Scholar
Guo H, German P, Bai S, Barnes S, Guo W, Qi X, et al. The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics. 2015;42(7):343–53.
Article
PubMed
PubMed Central
Google Scholar
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–9.
Article
PubMed Central
Google Scholar
Akbani R, Ng PKS, Werner HMJ, Shahmoradgoli M, Zhang F, Ju Z, et al. A pan-cancer proteomic perspective on the cancer genome atlas. Nat Commun. 2014;5:3887.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–44.
Article
CAS
PubMed
PubMed Central
Google Scholar